LifeStance Health
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encom...
Latest News
8 days ago · zacks.com
Surging Earnings Estimates Signal Upside for LifeStance Health (LFST) StockLifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
8 days ago · globenewswire.com
LifeStance Health Group Announces Pricing of Secondary Public OfferingSCOTTSDALE, Ariz., Nov. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 45,000,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”), at a public offering price of $13.12 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) from certain stockholders of the Company (the “Selling Stockholders”).
8 days ago · globenewswire.com
LifeStance Health Group Announces Launch of Secondary Public OfferingSCOTTSDALE, Ariz., Nov. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation's largest providers of virtual and in-person outpatient mental health care, today announced that pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”), certain stockholders of the Company (the “Selling Stockholders”) intend to offer 45,000,000 shares of LifeStance's common stock, par value $0.01 per share (the “Common Stock”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering.
11 days ago · zacks.com
What Makes LifeStance Health Group (LFST) a Strong Momentum Stock: Buy Now?Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
11 days ago · zacks.com
LifeStance Health Group, Inc. (LFST) Hits Fresh High: Is There Still Room to Run?LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
11 days ago · marketbeat.com
What LifeStance Health Group (LFST) Said on Its Q3 Earnings CallLifeStance Health Group NASDAQ: LFST raised its full-year 2026 outlook after reporting 25% third-quarter revenue growth, driven by more patient visits and higher revenue per visit. The mental health care provider also said its planned electronic health record transition could temper revenue growth in 2027.
12 days ago · seekingalpha.com
LifeStance Health Group, Inc. (LFST) Q3 2026 Earnings Call TranscriptLifeStance Health Group, Inc. (LFST) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
LifeStance Health Group (LFST) Tops Q3 Earnings and Revenue EstimatesLifeStance Health Group (LFST) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to break-even earnings per share a year ago.
12 days ago · globenewswire.com
LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year OutlookSCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2026.
19 days ago · prnewswire.com
LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data ShowsLifeStance Expands Specialty Services, Increasing Access to Esketamine (Spravato) and Transcranial Magnetic Stimulation (TMS) Across the U.S. SCOTTSDALE, Ariz., Oct. 29, 2026 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental healthcare, is expanding access to two specialty services for treatment-resistant depression – esketamine1 (Spravato) and transcranial magnetic stimulation2 (TMS) – as separate analyses show meaningful reductions in depression symptoms and suicidal ideation among patients receiving each treatment.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LFST